Key facts
- This page summarizes Christopher M. Smith's Form 4 filing for Ortho Clinical Diagnostics Holdings plc.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Jun 2022, 16:15.
Christopher M. Smith - 27 May 2022 Form 4 Insider Report for Ortho Clinical Diagnostics Holdings plc
- Form type
- 4
- Accepted by SEC
- 01 Jun 2022, 16:15:42 UTC
- Previous filing
- 05 Jan 2022
- Next filing
- 08 Jun 2022
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Michael A. Schlesinger, Attorney-in-Fact
SEC evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher M. Smith filed Form 4 for Ortho Clinical Diagnostics Holdings plc on 01 Jun 2022.
Change
- Previous filing in this sequence was filed on 05 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCDX
transaction
Ordinary Shares, $0.00001 par value
Disposed to Issuer
- Transaction value
- Shares
- -367,360
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 May 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCDX
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -1,971,420
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 May 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares, $0.00001 par value
- Underlying amount
- 1,971,420
- Exercise price
- $12.56
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Christopher M. Smith is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time, each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash.
Footnote F2
At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms.